Market Place
Sourcing Support
RemeGen`s Marketing Application for Telitaccept Accepted in China
29 Oct 2024 //
PR NEWSWIRE
RemeGen: ASCO 2024 Highlights Global Cancer Innovation
05 Jun 2024 //
PR NEWSWIRE
RemeGen`s RC88 ADC Shows Proof-Of-Concept Phase 1/2 Results
03 Jun 2024 //
PR NEWSWIRE
RemeGen Completes IgA Nephropathy, Sjögren`s Phase 3 Enrollment
21 May 2024 //
PR NEWSWIRE
RemeGen Shares Lupus Knowledge On World Lupus Day 2024
10 May 2024 //
PR NEWSWIRE
RemeGen`s Telitacicept Granted Fast Track Designation by FDA
02 Apr 2024 //
PR NEWSWIRE
RemeGen Presents Presentation on Evaluation of Its Proprietary Disitamab Vedotin
10 Mar 2024 //
PR NEWSWIRE
World Cancer Day 2024: RemeGen Announces Three Significant Developments
02 Feb 2024 //
PR NEWSWIRE
RemeGen`s RC88 Obtained FDA Fast Track Designation
12 Jan 2024 //
PR NEWSWIRE
RemeGen Announces Continued Inclusion of Telitacicept in Reimbursement Drug List
18 Dec 2023 //
PR NEWSWIRE
RemeGen Announces Publication of Results from Phase II for Disitamab Vedotin
27 Nov 2023 //
PR NEWSWIRE
RemeGen to Present Telitacicept PIII Trial Results for Rheumatoid Arthritis
15 Nov 2023 //
PR NEWSWIRE
RemeGen`s Telitacicept Shows Promise in PII Trial for Primary Sjogren`s Syndrome
25 Jul 2023 //
PR NEWSWIRE
RemeGen & Innovent Collaborate on Trials to Evaluate Potential of RC88 and RC108
10 Jul 2023 //
PR NEWSWIRE
Innovent & RemeGen Enter into Trial Collab Invesg Combination Therapy of TYVYT
25 Jun 2023 //
PR NEWSWIRE
RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer
05 Jun 2023 //
PR NEWSWIRE
RemeGen Shows Profitability to Receive Approval from Hong Kong Stock Exchange
05 Jun 2023 //
PR NEWSWIRE
RemeGen Celebrates World Intellectual Property Day 2023
25 Apr 2023 //
PR NEWSWIRE
RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy
27 Feb 2023 //
PR NEWSWIRE
RemeGen`s RC118 for Injection Granted Two Orphan Drug Designations by FDA
12 Dec 2022 //
PRNEWSWIRE
RemeGen Biosciences to Attend ASN Kidney Week 2022
03 Nov 2022 //
PRNEWSWIRE
RemeGen Releases Phase II Study Data for Treatment of Myasthenia Gravis
31 Oct 2022 //
PRNEWSWIRE
RemeGen receives ODD for myasthenia gravis treatment
14 Oct 2022 //
EUROPEANPHARMACEUTICALREVIEW
RemeGen Receives Orphan Drug Designation from FDA for Telitacicept
12 Oct 2022 //
PRNEWSWIRE
RemeGen Announces Results of PIII Study of Telitacicept
19 Sep 2022 //
PRNEWSWIRE
RemeGen Commemorates International Self-Care Day with Health Initiatives
25 Jul 2022 //
PRNEWSWIRE
RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO
24 May 2022 //
ASIAONE
Regulatory roundup: AbbVie’s Phase II fail plunges Alzheimer’s contender’s shot
23 Nov 2021 //
CLINICALTRIALSARENA
Seagen undaunted by AstraZeneca-Daiichi`s Enhertu
30 Oct 2021 //
FIERCEPHARMA
Seagen bets up to $2.6B on China’s first homemade ADC
10 Aug 2021 //
FIERCEPHARMA
ADC experts at Seagen find a $2.6B HER2 gem in China
09 Aug 2021 //
ENDPTS
RemeGen grabs one of the world`s largest ever biotech IPOs
09 Nov 2020 //
FIERCE BIOTECH
USFDA Breakthrough Therapy Designation for RemeGen`s Disitamab Vedotin (RC48)
25 Sep 2020 //
PRESS RELEASE
RemeGen Announces US FDA Clearance of IND Application to Initiate Phase II trial
29 Apr 2020 //
PR NEWSWIRE
FDA Grants Fast Track Designation to RemeGen`s Telitacicept
15 Apr 2020 //
PR NEWSWIRE
